Copanlisib dihydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Copanlisib diHClide 是一种 ATP 竞争性泛 I 类 PI3K 抑制剂（PI3Kα、PI3Kδ、PI3Kβ 和 PI3Kγ 的 IC50 值：0.5 nM、0.7 nM、3.7 nM 和 6.4 nM）。

Copanlisib dihydrochloride is an ATP-competitive pan-class I PI3K inhibitor (IC50s: 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ). Copanlisib dihydrochloride has superior antitumor activity and it also has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. (In Vitro):Copanlisib (BAY 80-6946; 20-200 nM; 24 hours; BT20 breast cancer cells) treatmemnt induces apoptosis in a subset of tumor cell lines that are resistant to Lapatinib and Trastuzumab.Copanlisib (BAY 80-6946; 0.5-500 nM; 2 hours; ELT3 cells) treatmemnt shows complete inhibition of PI3K-mediated AKT phosphorylation in ELT3 cells. Copanlisib potently inhibits cell proliferation in a panel of human tumor cell lines. Copanlisib has mean IC50 values of 19 nM against cell lines with PIK3CA-activating mutations and 17 nM against HER2-positive cell lines, whereas the activity in PIK3CA wild-type and HER2-negative cells is about 40-fold less potent.(In Vivo):Copanlisib (BAY 80-6946; 0.5-6 mg/kg; intravenous injection; every second day, every third day; for 60 days; athymic nude rats) treatment displays robust antitumor activity in the rat KPL4 tumor xenograft model.

Copanlisib (BAY 80-6946; 20-200 nM; 24 hours; BT20 breast cancer cells) treatmemnt induces apoptosis in a subset of tumor cell lines that are resistant to Lapatinib and Trastuzumab.Copanlisib (BAY 80-6946; 0.5-500 nM; 2 hours; ELT3 cells) treatmemnt shows complete inhibition of PI3K-mediated AKT phosphorylation in ELT3 cells.Copanlisib potently inhibits cell proliferation in a panel of human tumor cell lines. Copanlisib has mean IC50 values of 19 nM against cell lines with PIK3CA-activating mutations and 17 nM against HER2-positive cell lines, whereas the activity in PIK3CA wild-type and HER2-negative cells is about 40-fold less potent. Apoptosis Analysis Cell Line:BT20 breast cancer cells Concentration:20 nM and 62 nM, 200 nM Incubation Time:24 hours Result:Significantly increased caspase9 activities. Also increased levels of phosphorylated p53 at Ser15and cleaved PARP. Induced caspase-9 activation with an EC50 of 340 nM.Western Blot Analysis Cell Line:ELT3 cells Concentration:0.5 nM, 5 nM, 50 nM, 500 nMIncubation Time:2 hours Result:Complete inhibition of PI3K-mediated AKT phosphorylation was clearly shown at a concentration of 5 nM.

Copanlisib (BAY 80-6946; 0.5-6 mg/kg; intravenous injection; every second day, every third day; for 60 days; athymic nude rats) treatment displays robust antitumor activity in the rat KPL4 tumor xenograft model. Animal Model:Athymic nude rats injected with KPL4 tumor cells Dosage:0.5 mg/kg, 1 mg/kg, 3 mg/kg or 6 mg/kg Administration:Intravenous injection; every second day, every third day; for 60 days Result: On day 25, tumor growth inhibition (TGI) rates of 77%, 84%, 99%, and 100% were observed at doses of 0.5, 1, 3, and 6 mg/kg, respectively. All rats remained tumor free at the termination of the study on day 73.

BAY 80-6946 dihydrochloride

PI3K/Akt/mTOR signaling

PI3K

PI3Kα|PI3Kδ|PI3Kβ|PI3Kγ|mTOR

——

——

1402152-13-9

553.44

C23H30Cl2N8O4

>98% (HPLC)

DMSO:10 mM

O=C(C1=CN=C(N)N=C1)NC2=NC3=C(C=CC(OCCCN4CCOCC4)=C3OC)C5=NCCN25.[H]Cl.[H]Cl

——

(-20℃)

With Ice Pack

≥ 2 years